User login
Blistering Diseases in Newborns
After, test your knowledge by answering the 5 practice questions.
Practice Questions
1. Which congenital blistering condition is caused by a mast cell growth factor receptor (KIT) mutation?
a. aplasia cutis congenita
b. bullous mastocytosis
c. congenital erosive and vesicular dermatosis
d. epidermolysis bullosa simplex
e. ichthyosis bullosa of Siemens
2. What gene mutation is present in acrodermatitis enteropathica?
a. collagen VII
b. keratin 2e
c. mast cell growth factor receptor
d. NF-κB essential modulator
e. solute carrier family 39 (zinc transporter), member 4
3. Which congenital blistering disease is associated with an increased risk of squamous cell carcinoma in adult patients?
a. aplasia cutis congenita
b. bullous mastocytosis
c. Kindler syndrome
d. pemphigus syphiliticus
e. varicella
4. Which congenital blistering condition can be caused by prenatal exposure to methimazole?
a. aplasia cutis congenita
b. bullous mastocytosis
c. dystrophic epidermolysis bullosa
d. Kindler syndrome
e. pemphigus syphiliticus
5. Which congenital blistering condition is caused by a mutation in transglutaminase 5?
a. acral peeling skin syndrome
b. aplasia cutis congenita
c. bullous mastocytosis
d. dystrophic epidermolysis bullosa
e. Kindler syndrome
1. Which congenital blistering condition is caused by a mast cell growth factor (KIT) receptor mutation?
a. aplasia cutis congenita
b. bullous mastocytosis
c. congenital erosive and vesicular dermatosis
d. epidermolysis bullosa simplex
e. ichthyosis bullosa of Siemens
2. What gene mutation is present in acrodermatitis enteropathica?
a. collagen VII
b. keratin 2e
c. mast cell growth factor receptor
d. NF-κB essential modulator
e. solute carrier family 39 (zinc transporter), member 4
3. Which congenital blistering disease is associated with an increased risk of squamous cell carcinoma in adult patients?
a. aplasia cutis congenita
b. bullous mastocytosis
c. Kindler syndrome
d. pemphigus syphiliticus
e. varicella
4. Which congenital blistering condition can be caused by prenatal exposure to methimazole?
a. aplasia cutis congenita
b. bullous mastocytosis
c. dystrophic epidermolysis bullosa
d. Kindler syndrome
e. pemphigus syphiliticus
5. Which congenital blistering condition is caused by a mutation in transglutaminase 5?
a. acral peeling skin syndrome
b. aplasia cutis congenita
c. bullous mastocytosis
d. dystrophic epidermolysis bullosa
e. Kindler syndrome
After, test your knowledge by answering the 5 practice questions.
Practice Questions
1. Which congenital blistering condition is caused by a mast cell growth factor receptor (KIT) mutation?
a. aplasia cutis congenita
b. bullous mastocytosis
c. congenital erosive and vesicular dermatosis
d. epidermolysis bullosa simplex
e. ichthyosis bullosa of Siemens
2. What gene mutation is present in acrodermatitis enteropathica?
a. collagen VII
b. keratin 2e
c. mast cell growth factor receptor
d. NF-κB essential modulator
e. solute carrier family 39 (zinc transporter), member 4
3. Which congenital blistering disease is associated with an increased risk of squamous cell carcinoma in adult patients?
a. aplasia cutis congenita
b. bullous mastocytosis
c. Kindler syndrome
d. pemphigus syphiliticus
e. varicella
4. Which congenital blistering condition can be caused by prenatal exposure to methimazole?
a. aplasia cutis congenita
b. bullous mastocytosis
c. dystrophic epidermolysis bullosa
d. Kindler syndrome
e. pemphigus syphiliticus
5. Which congenital blistering condition is caused by a mutation in transglutaminase 5?
a. acral peeling skin syndrome
b. aplasia cutis congenita
c. bullous mastocytosis
d. dystrophic epidermolysis bullosa
e. Kindler syndrome
1. Which congenital blistering condition is caused by a mast cell growth factor (KIT) receptor mutation?
a. aplasia cutis congenita
b. bullous mastocytosis
c. congenital erosive and vesicular dermatosis
d. epidermolysis bullosa simplex
e. ichthyosis bullosa of Siemens
2. What gene mutation is present in acrodermatitis enteropathica?
a. collagen VII
b. keratin 2e
c. mast cell growth factor receptor
d. NF-κB essential modulator
e. solute carrier family 39 (zinc transporter), member 4
3. Which congenital blistering disease is associated with an increased risk of squamous cell carcinoma in adult patients?
a. aplasia cutis congenita
b. bullous mastocytosis
c. Kindler syndrome
d. pemphigus syphiliticus
e. varicella
4. Which congenital blistering condition can be caused by prenatal exposure to methimazole?
a. aplasia cutis congenita
b. bullous mastocytosis
c. dystrophic epidermolysis bullosa
d. Kindler syndrome
e. pemphigus syphiliticus
5. Which congenital blistering condition is caused by a mutation in transglutaminase 5?
a. acral peeling skin syndrome
b. aplasia cutis congenita
c. bullous mastocytosis
d. dystrophic epidermolysis bullosa
e. Kindler syndrome
After, test your knowledge by answering the 5 practice questions.
Practice Questions
1. Which congenital blistering condition is caused by a mast cell growth factor receptor (KIT) mutation?
a. aplasia cutis congenita
b. bullous mastocytosis
c. congenital erosive and vesicular dermatosis
d. epidermolysis bullosa simplex
e. ichthyosis bullosa of Siemens
2. What gene mutation is present in acrodermatitis enteropathica?
a. collagen VII
b. keratin 2e
c. mast cell growth factor receptor
d. NF-κB essential modulator
e. solute carrier family 39 (zinc transporter), member 4
3. Which congenital blistering disease is associated with an increased risk of squamous cell carcinoma in adult patients?
a. aplasia cutis congenita
b. bullous mastocytosis
c. Kindler syndrome
d. pemphigus syphiliticus
e. varicella
4. Which congenital blistering condition can be caused by prenatal exposure to methimazole?
a. aplasia cutis congenita
b. bullous mastocytosis
c. dystrophic epidermolysis bullosa
d. Kindler syndrome
e. pemphigus syphiliticus
5. Which congenital blistering condition is caused by a mutation in transglutaminase 5?
a. acral peeling skin syndrome
b. aplasia cutis congenita
c. bullous mastocytosis
d. dystrophic epidermolysis bullosa
e. Kindler syndrome
1. Which congenital blistering condition is caused by a mast cell growth factor (KIT) receptor mutation?
a. aplasia cutis congenita
b. bullous mastocytosis
c. congenital erosive and vesicular dermatosis
d. epidermolysis bullosa simplex
e. ichthyosis bullosa of Siemens
2. What gene mutation is present in acrodermatitis enteropathica?
a. collagen VII
b. keratin 2e
c. mast cell growth factor receptor
d. NF-κB essential modulator
e. solute carrier family 39 (zinc transporter), member 4
3. Which congenital blistering disease is associated with an increased risk of squamous cell carcinoma in adult patients?
a. aplasia cutis congenita
b. bullous mastocytosis
c. Kindler syndrome
d. pemphigus syphiliticus
e. varicella
4. Which congenital blistering condition can be caused by prenatal exposure to methimazole?
a. aplasia cutis congenita
b. bullous mastocytosis
c. dystrophic epidermolysis bullosa
d. Kindler syndrome
e. pemphigus syphiliticus
5. Which congenital blistering condition is caused by a mutation in transglutaminase 5?
a. acral peeling skin syndrome
b. aplasia cutis congenita
c. bullous mastocytosis
d. dystrophic epidermolysis bullosa
e. Kindler syndrome
Medications for Advanced Melanoma
After, test your knowledge by answering the 5 practice questions.
Practice Questions
1. Which of the following medications is considered an MEK inhibitor?
a. aldesleukin
b. dacarbazine
c. ipilimumab
d. recombinant interferon alfa-2b
e. trametinib
2. Which of the following medications has been shown to be associated with toxic epidermal necrolysis?
a. aldesleukin
b. dacarbazine
c. ipilimumab
d. recombinant interferon alfa-2b
e. trametinib
3. What medication can be administered as a subcutaneous injection?
a. aldesleukin
b. dacarbazine
c. ipilimumab
d. recombinant interferon alfa-2b
e. trametinib
4. Which of the following medications is a monoclonal antibody to cytotoxic T-lymphocyte–associated antigen 4?
a. aldesleukin
b. dacarbazine
c. ipilimumab
d. recombinant interferon alfa-2b
e. trametinib
5. Which of the following medications is an IL-2 cytokine?
a. aldesleukin
b. dacarbazine
c. ipilimumab
d. recombinant interferon alfa-2b
e. trametinib
The answers appear on the next page.
Practice Question Answers
1. Which of the following medications is considered an MEK inhibitor?
a. aldesleukin
b. dacarbazine
c. ipilimumab
d. recombinant interferon alfa-2b
e. trametinib
2. Which of the following medications has been shown to be associated with toxic epidermal necrolysis?
a. aldesleukin
b. dacarbazine
c. ipilimumab
d. recombinant interferon alfa-2b
e. trametinib
3. What medication can be administered as a subcutaneous injection?
a. aldesleukin
b. dacarbazine
c. ipilimumab
d. recombinant interferon alfa-2b
e. trametinib
4. Which of the following medications is a monoclonal antibody to cytotoxic T-lymphocyte–associated antigen 4?
a. aldesleukin
b. dacarbazine
c. ipilimumab
d. recombinant interferon alfa-2b
e. trametinib
5. Which of the following medications is an IL-2 cytokine?
a. aldesleukin
b. dacarbazine
c. ipilimumab
d. recombinant interferon alfa-2b
e. trametinib
After, test your knowledge by answering the 5 practice questions.
Practice Questions
1. Which of the following medications is considered an MEK inhibitor?
a. aldesleukin
b. dacarbazine
c. ipilimumab
d. recombinant interferon alfa-2b
e. trametinib
2. Which of the following medications has been shown to be associated with toxic epidermal necrolysis?
a. aldesleukin
b. dacarbazine
c. ipilimumab
d. recombinant interferon alfa-2b
e. trametinib
3. What medication can be administered as a subcutaneous injection?
a. aldesleukin
b. dacarbazine
c. ipilimumab
d. recombinant interferon alfa-2b
e. trametinib
4. Which of the following medications is a monoclonal antibody to cytotoxic T-lymphocyte–associated antigen 4?
a. aldesleukin
b. dacarbazine
c. ipilimumab
d. recombinant interferon alfa-2b
e. trametinib
5. Which of the following medications is an IL-2 cytokine?
a. aldesleukin
b. dacarbazine
c. ipilimumab
d. recombinant interferon alfa-2b
e. trametinib
The answers appear on the next page.
Practice Question Answers
1. Which of the following medications is considered an MEK inhibitor?
a. aldesleukin
b. dacarbazine
c. ipilimumab
d. recombinant interferon alfa-2b
e. trametinib
2. Which of the following medications has been shown to be associated with toxic epidermal necrolysis?
a. aldesleukin
b. dacarbazine
c. ipilimumab
d. recombinant interferon alfa-2b
e. trametinib
3. What medication can be administered as a subcutaneous injection?
a. aldesleukin
b. dacarbazine
c. ipilimumab
d. recombinant interferon alfa-2b
e. trametinib
4. Which of the following medications is a monoclonal antibody to cytotoxic T-lymphocyte–associated antigen 4?
a. aldesleukin
b. dacarbazine
c. ipilimumab
d. recombinant interferon alfa-2b
e. trametinib
5. Which of the following medications is an IL-2 cytokine?
a. aldesleukin
b. dacarbazine
c. ipilimumab
d. recombinant interferon alfa-2b
e. trametinib
After, test your knowledge by answering the 5 practice questions.
Practice Questions
1. Which of the following medications is considered an MEK inhibitor?
a. aldesleukin
b. dacarbazine
c. ipilimumab
d. recombinant interferon alfa-2b
e. trametinib
2. Which of the following medications has been shown to be associated with toxic epidermal necrolysis?
a. aldesleukin
b. dacarbazine
c. ipilimumab
d. recombinant interferon alfa-2b
e. trametinib
3. What medication can be administered as a subcutaneous injection?
a. aldesleukin
b. dacarbazine
c. ipilimumab
d. recombinant interferon alfa-2b
e. trametinib
4. Which of the following medications is a monoclonal antibody to cytotoxic T-lymphocyte–associated antigen 4?
a. aldesleukin
b. dacarbazine
c. ipilimumab
d. recombinant interferon alfa-2b
e. trametinib
5. Which of the following medications is an IL-2 cytokine?
a. aldesleukin
b. dacarbazine
c. ipilimumab
d. recombinant interferon alfa-2b
e. trametinib
The answers appear on the next page.
Practice Question Answers
1. Which of the following medications is considered an MEK inhibitor?
a. aldesleukin
b. dacarbazine
c. ipilimumab
d. recombinant interferon alfa-2b
e. trametinib
2. Which of the following medications has been shown to be associated with toxic epidermal necrolysis?
a. aldesleukin
b. dacarbazine
c. ipilimumab
d. recombinant interferon alfa-2b
e. trametinib
3. What medication can be administered as a subcutaneous injection?
a. aldesleukin
b. dacarbazine
c. ipilimumab
d. recombinant interferon alfa-2b
e. trametinib
4. Which of the following medications is a monoclonal antibody to cytotoxic T-lymphocyte–associated antigen 4?
a. aldesleukin
b. dacarbazine
c. ipilimumab
d. recombinant interferon alfa-2b
e. trametinib
5. Which of the following medications is an IL-2 cytokine?
a. aldesleukin
b. dacarbazine
c. ipilimumab
d. recombinant interferon alfa-2b
e. trametinib